TollB-001 / Toll Biotech - LARVOL DELTA

Advances and challenges in Toll-like receptor-targeted therapy for rheumatoid arthritis. (PubMed, Drug Discov Today) - "Representative agents such as OPN-305, OPN-301, imiquimod, and antidepressants have demonstrated therapeutic potential by modulating TLR signaling in RA pathological manifestations. TollB-001, a novel small molecular drug, represents a potential breakthrough in RA therapy. Despite promising preclinical and clinical outcomes with agents including IMO-3100, DV-1179, and R848, challenges remain regarding efficacy variability and immune-related safety. This review aims to provide insights into TLR-based interventions and inform the development of future strategies for more effective management."

Journal • Review • Immunology • Inflammation • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Tolling Biotech's Category 1 rare disease new drug obtains FDA clinical approval for systemic sclerosis [Google translation] (Sina Corp) - "On February 5, Toll Biotech announced that its rare disease category 1 new drug TollB-001 tablets, following the clinical approval by China's NMPA on December 30, 2024, has been approved by the US FDA for the treatment of systemic sclerosis. This progress marks another important step for Toll Biotech in the field of global autoimmune diseases."

China approval • FDA approval • Systemic Sclerosis

A Study of Single and Multiple Oral Doses of TollB-001 (clinicaltrials.gov) - P1 | N=122 | Recruiting | Sponsor: Toll Biotech Co. Ltd. (Beijing)

New P1 trial • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology